WESTLAKE VILLAGE, Calif. — August 8, 2025 — Leads & Copy — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has granted 21,000 restricted stock units to three newly hired employees. The awards, approved by the Compensation Committee of Arcutis’ Board of Directors under the 2022 Inducement Plan, were granted on August 1, 2025, as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25 percent vesting annually, subject to continuous employment with Arcutis. Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
Amanda Sheldon, Head of Corporate Communications, media@arcutis.com
Brian Schoelkopf, Head of Investor Relations, ir@arcutis.com
Source: Arcutis Biotherapeutics, Inc.
